• Utilizing ASOs as a novel way to modulate NaV1.7, which can circumvent the existing issues with small molecule inhibitors (e.g. autonomic side effects)
• Exploring how Quiver’s integrated platform based on all-optical electrophysiology and machine learning has led to identifying novel candidate molecules alongside therapeutic targets
• Demonstrating how Quiver’s platform can enrich the genetic medicine drug candidates with maximized therapeutic index

New Data